ClinicalTrials.gg
CompletedNCT01892020Updated Jul 9, 2015Results posted

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

A Phase 4 interventional study of biphasic insulin aspart 50 and biphasic human insulin 50 in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-07-09.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 2.

Enrollment
39th of 76
161 · median 163
Started
2013
with 2 others
Phase 4
34 of 76
1 open now
Registered
66th of 76
by date
Lead sponsor
60 of 76
Novo Nordisk A/S

Among the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment, is one of 3 that started in 2013, is one of 34 in phase 4, and was the 66th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2 is open now. Recruiting first, the newest first:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies testing Insulin Aspart in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50 (BHI 50) twice daily, both in combination with metformin, in Chinese subjects with type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 161 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (diagnosed clinically) for at least 12 months
  • Currently treated with premixed human insulin 50 BID for at least 3 months prior to screening visit (Visit 1)
  • Currently treated with unchanged total daily dose of at least 1500 mg metformin or maximum tolerated dose at least 1000 mg/day metformin for at least 2 months prior to screening visit
  • Glycosylated () 7.0% and 9.0% (both inclusive) (central laboratory)

Exclusion criteria

Exclusion Criteria:

  • Treatment with any insulin secretagogue, alfa-glucosidase inhibitors, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 (GLP-1) receptor agonists within the last 3 months prior to screening
  • Previous use of any insulin other than premixed human insulin 50 BID within 3 months prior to Visit 1
  • Previous use of insulin intensification treatment (premixed insulin thrice daily, basal bolus regimen, and continuous subcutaneous insulin infusion (CSII)) for more than 14 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Treatment sequence 1 (Group A)

    Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)

    Drug: biphasic insulin aspart 50 · Drug: biphasic human insulin 50

  • Experimental
    Treatment sequence 2 (Group B)

    Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)

    Drug: biphasic insulin aspart 50 · Drug: biphasic human insulin 50

Interventions

  • Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

  • Drugbiphasic human insulin 50

    Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

07

What researchers measure

Primary outcomes

  1. 2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test

    The 2-hour PPG increment is the difference between the plasma glucose (PG) value at 120 minutes after standard meal test and the fasting PG value.

    Time frame: After 4 weeks of treatment in each treatment sequence

Secondary outcomes

  1. -1-hour PPG Increment Following a Standard Meal Test

    The 1-h PPG increment is the difference between the plasma glucose (PG) value at 60 minutes after standard meal test and the fasting PG value.

    Time frame: After 4 weeks of treatment in each treatment sequence

  2. -IAUC (Incremental Area Under the Curve) for PPG (0-2 Hours) Following a Standard Meal Test

    AUC for plasma glucose was calculated by the trapezoidal method using 30-min sampling time points, and IAUC for PPG (0-2h) data was analyzed using a normal linear mixed model.

    Time frame: After 4 weeks of treatment in each treatment sequence

  3. 2-hour PPG Increments Over Each of the 3 Main Meals in 8-point SMPG (Self-measured Plasma Glucose) Profile

    PPG increments over each of the 3 main meals were derived from the 8-point SMPG profile as the difference between PG values available 120 minutes after meal and before meal.

    Time frame: After 4 weeks of treatment in each treatment sequence

  4. The Mean 2-hour PPG Increments of the 3 Main Meals in 8-point SMPG Profile

    Mean post prandial PG increment over all meals was derived as the mean of all available meal increments.

    Time frame: After 4 weeks of treatment in each treatment sequence

  5. Incidence of Hypoglycemic Episodes

    Treatment Emergent Hypoglycemic Episode refers to those the onset of the episode is on or after the first day of exposure to randomized treatment and no later than the last day of randomized treatment. Results are presented by American Diabetes Association classification of hypoglycemia.

    Time frame: During 4 weeks of treatment in each treatment sequence

  6. Incidence of AEs (Adverse Event)

    Treatment emergent AE (TEAE) is defined as an event that has onset date on or after the first day of exposure to randomized treatment and no later than the last day of randomized treatment.

    Time frame: During 4 weeks of treatment in each treatment sequence

08

Results

Posted Jul 9, 2015

Participant flow

This trial was conducted in 14 sites in one country (China).

Period 1
Participant flow — Period 1
MilestoneGroup A (BIAsp 50 - BHI 50)Group B (BHI 50 - BIAsp 50)
Started8180
Completed7874
Not completed36
Withdrew: Adverse event11
Withdrew: Protocol violation24
Withdrew: Unclassified01
Period 2
Participant flow — Period 2
MilestoneGroup A (BIAsp 50 - BHI 50)Group B (BHI 50 - BIAsp 50)
Started7874
Completed7774
Not completed10
Withdrew: Protocol violation10

Outcome measures

Primary2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test

The 2-hour PPG increment is the difference between the plasma glucose (PG) value at 120 minutes after standard meal test and the fasting PG value.

Time frame:
After 4 weeks of treatment in each treatment sequence
Reported as:
Mean · mmol/L
2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test
mmol/LBIAsp 50BHI 50
2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test5.30 ± 3.176.41 ± 2.83
Statistical analysis
  • BIAsp 50 vs BHI 50 · Mixed Models Analysis · p = < 0.001 (The 2-h PPG increment was analyzed using a normal linear mixed model with period and treatment as fixed effects and subject as a random effect.) · Mean difference (net): -1.12 · 95% CI -1.66 to -0.58
Secondary-1-hour PPG Increment Following a Standard Meal Test

The 1-h PPG increment is the difference between the plasma glucose (PG) value at 60 minutes after standard meal test and the fasting PG value.

Time frame:
After 4 weeks of treatment in each treatment sequence
Reported as:
Mean · mmol/L
-1-hour PPG Increment Following a Standard Meal Test
mmol/LBIAsp 50BHI 50
-1-hour PPG Increment Following a Standard Meal Test4.42 ± 2.494.74 ± 2.24
Secondary-IAUC (Incremental Area Under the Curve) for PPG (0-2 Hours) Following a Standard Meal Test

AUC for plasma glucose was calculated by the trapezoidal method using 30-min sampling time points, and IAUC for PPG (0-2h) data was analyzed using a normal linear mixed model.

Time frame:
After 4 weeks of treatment in each treatment sequence
Reported as:
Mean · min*mmol/L
-IAUC (Incremental Area Under the Curve) for PPG (0-2 Hours) Following a Standard Meal Test
min*mmol/LBIAsp 50BHI 50
-IAUC (Incremental Area Under the Curve) for PPG (0-2 Hours) Following a Standard Meal Test465.39 ± 228503.64 ± 215
Secondary2-hour PPG Increments Over Each of the 3 Main Meals in 8-point SMPG (Self-measured Plasma Glucose) Profile

PPG increments over each of the 3 main meals were derived from the 8-point SMPG profile as the difference between PG values available 120 minutes after meal and before meal.

Time frame:
After 4 weeks of treatment in each treatment sequence
Reported as:
Least squares mean · mmol/L
2-hour PPG Increments Over Each of the 3 Main Meals in 8-point SMPG (Self-measured Plasma Glucose) Profile
mmol/LBIAsp 50BHI 50
Increment at breakfast, N=151, 1492.52 ± 0.202.86 ± 0.20
Increment at Lunch, N=150, 1483.58 ± 0.262.93 ± 0.26
Increment at dinner, N=151, 1491.08 ± 0.260.99 ± 0.26
SecondaryThe Mean 2-hour PPG Increments of the 3 Main Meals in 8-point SMPG Profile

Mean post prandial PG increment over all meals was derived as the mean of all available meal increments.

Time frame:
After 4 weeks of treatment in each treatment sequence
Reported as:
Least squares mean · mmol/L
The Mean 2-hour PPG Increments of the 3 Main Meals in 8-point SMPG Profile
mmol/LBIAsp 50BHI 50
The Mean 2-hour PPG Increments of the 3 Main Meals in 8-point SMPG Profile2.39 ± 0.152.25 ± 0.15
SecondaryIncidence of Hypoglycemic Episodes

Treatment Emergent Hypoglycemic Episode refers to those the onset of the episode is on or after the first day of exposure to randomized treatment and no later than the last day of randomized treatment. Results are presented by American Diabetes Association classification of hypoglycemia.

Time frame:
During 4 weeks of treatment in each treatment sequence
Reported as:
Number · events per patient per year
Incidence of Hypoglycemic Episodes
events per patient per yearBIAsp 50BHI 50
All events12.1014.38
Severe00.08
Documented Symptomatic5.978.33
Asymptomatic1.292.53
Probable Symptomatic2.581.72
Relative2.101.72
Unclassifiable0.160
SecondaryIncidence of AEs (Adverse Event)

Treatment emergent AE (TEAE) is defined as an event that has onset date on or after the first day of exposure to randomized treatment and no later than the last day of randomized treatment.

Time frame:
During 4 weeks of treatment in each treatment sequence
Reported as:
Number · Events/100 years of patient exposure
Incidence of AEs (Adverse Event)
Events/100 years of patient exposureBIAsp 50BHI 50
Incidence of AEs (Adverse Event)322.7245.1

Adverse events

Collected over An event with onset date on or after the first day of exposure to randomized treatment and no later than the last day of randomized treatment was defined as treatment emergent AE. All events meeting this definition were collected and reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIAsp 50—1/155 (0.6%)8/155 (5.2%)
BHI 50—1/158 (0.6%)2/158 (1.3%)
Most frequent serious events
Most frequent serious events
EventBIAsp 50BHI 50
Cerebral infarctionNervous system disorders1/1550/158
Small intestinal haemorrhageGeneral disorders0/1551/158
Most frequent other events
Most frequent other events
EventBIAsp 50BHI 50
HyperlipidaemiaMetabolism and nutrition disorders8/1552/158

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects
Mean59.1 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female88
Male73
09

Study locations

1 site
  • Beijing, Beijing 100034, China
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2013
First posted
Jul 3, 2013
Start
Jun 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Jul 9, 2015
Last update
Jul 9, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01892020
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jul 3, 2013
Start date
Jun 2013
Primary completion
May 2014
Completion
May 2014
Results posted
Jul 9, 2015
Last update
Jul 9, 2015

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion